Publications by authors named "Haefaa Alchalby"

Claim this Profile
I
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
Nicolaus Kröger, Victoria Panagiota, Anita Badbaran, Tatjana Zabelina, Ioanna Triviai, Haefaa Alchalby

Biol Blood Marrow Transplant· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis.
Thorsten Derlin, Haefaa Alchalby, Peter Bannas, Azien Laqmani, Francis Ayuk

J Nucl Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Marie Robin, Raphael Porcher, Christine Wolschke, Flore Sicre de Fontbrune, Haefaa Alchalby

Biol Blood Marrow Transplant· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis.
Kais Hussein, Angelika Stucki-Koch, Haefaa Alchalby, Ioanna Triviai, Nicolaus Kröger

Biol Blood Marrow Transplant· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.
Francis Ayuk, Ronja Veit, Tatjana Zabelina, Lara Bussmann, Maximilian Christopeit, Haefaa Alchalby

Ann Hematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Sowmya Parampalli Yajnanarayana, Thomas Stübig, Isabelle Cornez, Haefaa Alchalby, Kathrin Schönberg

Br J Haematol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.
Nicolaus Kröger, Toni Giorgino, Bart L Scott, Markus Ditschkowski, Haefaa Alchalby

Blood· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study.
Thorsten Derlin, Haefaa Alchalby, Peter Bannas, Simon Veldhoen, Ivayla Apostolova

Eur J Nucl Med Mol Imaging· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Haefaa Alchalby, Nicolaus Kröger

Clin Lymphoma Myeloma Leuk· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Nicolaus Kröger, Tatjana Zabelina, Haefaa Alchalby, Thomas Stübig, Christine Wolschke

Biol Blood Marrow Transplant· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.
Francis Ayuk, Lara Bussmann, Tatjana Zabelina, Ronja Veit, Haefaa Alchalby

Ann Hematol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.
Evgeny Klyuchnikov, Jean El-Cheikh, Andreas Sputtek, Michael Lioznov, Boris Calmels, Haefaa Alchalby

Biol Blood Marrow Transplant· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
Haefaa Alchalby, Tatjana Zabelina, Thomas Stübig, Anja van Biezen, Martin Bornhäuser

Biol Blood Marrow Transplant· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Anthony Oyekunle, Axel R Zander, Mascha Binder, Francis Ayuk, Tatjana Zabelina, Haefaa Alchalby

Ann Hematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Nicolaus Kröger, Anita Badbaran, Tatjana Zabelina, Francis Ayuk, Christine Wolschke, Haefaa Alchalby

Biol Blood Marrow Transplant· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Haefaa Alchalby, Dinah-Rohina Yunus, Tatjana Zabelina, Guido Kobbe, Ernst Holler

Br J Haematol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Bettina Wiedemann, Evgeny Klyuchnikov, Nicolaus Kröger, Tatjana Zabelina, Tanja Stahl, Haefaa Alchalby

Exp Hematol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Haefaa Alchalby, Anita Badbaran, Tatjana Zabelina, Guido Kobbe, Joachim Hahn

Blood· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Ulrike Bacher, Svetlana Asenova, Anita Badbaran, Axel Rolf Zander, Haefaa Alchalby

Clin Exp Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.
Haefaa Alchalby, Nicolaus Kröger

Curr Hematol Malig Rep· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Nicolaus Kröger, Haefaa Alchalby, Evgeny Klyuchnikov, Anita Badbaran, York Hildebrandt

Blood· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis